mrna-1345
Trade name: mRESVIA
Vaccineapproved
Approved
May 31, 2024
Clinical trial activity
11 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
6
Phase 3
5
Phase 4
0
Earliest trial started Sep 30, 2020 (NCT04528719)
Timeline
Indications
Approved for
Mechanism of action
- RSV F-proteinImmunity, active
RSV F-protein immunity, active
Approval history
- approvedMay 31, 2024
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07117487 | Phase 3 | Aug 5, 2025 | Moderna Therapeutics |
| NCT06143046 | Phase 2 | Nov 15, 2023 | Moderna Therapeutics |
| NCT06097299 | Phase 2 | Oct 24, 2023 | Moderna Therapeutics |
| NCT06067230 | Phase 3 | Oct 6, 2023 | Moderna Therapeutics |
| NCT06060457 | Phase 3 | Sep 25, 2023 | Moderna Therapeutics |
| NCT05743881 | Phase 1 | Feb 15, 2023 | Moderna Therapeutics |
| NCT05585632 | Phase 1 | Oct 14, 2022 | Moderna Therapeutics |
| NCT05397223 | Phase 1 | May 24, 2022 | Moderna Therapeutics |
| NCT05330975 | Phase 3 | Apr 1, 2022 | Moderna Therapeutics |
| NCT05127434 | Phase 2/Phase 3 (Phase 3) | Nov 12, 2021 | Moderna Therapeutics |
| NCT04528719 | Phase 1 | Sep 30, 2020 | Moderna Therapeutics |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Moderna Therapeutics | For profit | 11 | 11 | 3 | 2020 |
1 organizations
Page 1 / 1